Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia
Main Article Content
Abstract
Background: Treating patients with multidrug-resistant tuberculosis (MDR-TB) strains is more complicated, complex, toxic, expensive, than treating patients with susceptible TB strains. This study aims to compare the treatment outcomes and potential factors associated between patients with MDR-TB and non MDR TB infections in peninsular Malaysia. Methods: This study was a retrospective cohort study. Data were collected from the medical records of all registered MDR-TB patients and Non-MDR-TB patients at five TB hospitals in peninsular Malaysia from January 2010 to January 2014. Results: A total of 314 subjects were studied, including 105 MDR-TB cases and 209 non-MDRTB. After TB treatment, 24.8% of the MDR-TB patients and 17.7% of non MDR TB relapsed; 17.1% of the MDR-TB patients and 16.3% of non MDR TB defaulted from TB treatment. A significant difference seen in treatment success rate 17.1% for MDR-TB; 63.1% for non MDR TB (P < 0.001)). Mortality rate were 8.9% for MDR-TB; 13.2% for non MDR TB. Multivariable analysis showed the potential factors associated with poor treatment outcomes were presence of HIV infection (AOR, 1.09; 95%CI: 1.05, 1.75; P = 0.001) and previous TB treatment (AOR, 4.87; 95%CI: 2.84, 8.38; P = 0.001). Conclusion: This study revealed that the treatment success rate in patients with non MDR TB infection was higher than MDR-TB. Unsuccessful treatment was seen in MDR-TB associated with potential factors such as history of TB treatment, and presence of HIV infection.
Article Details
Issue
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet. 2003; 362:887–899. http://dx.doi.org/10.1016/S0140-6736(03)14333-4
Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006; 368:2142–2154. http://dx.doi.org/10.1016/S0140-6736(06)69863-2
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368:1575–1580. http://dx.doi.org/10.1016/S0140-6736(06)69573-1
Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrugresistant tuberculosis. J Infect Dis. 2006; 194:479–485. http://dx.doi.org/10.1086/505877
Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova O, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Resir J. 2007; 30:623–626. http://dx.doi.org/10.1183/09031936.00077307
Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, et al. Treatment outcomes and longterm survival in patients with extensively drugresistant tuberculosis. Am J Respir Crit Care Med. 2008:178:1075–1082. http://dx.doi.org/10.1164/rccm.200801-132OC
Udwadia ZF. XDR-TB in India: when will we heed the alarm? J Assoc Physicians India.2008; 56:409–410.
Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: review. Curr Opin Infect Dis. 2008; 21:587–595. http://dx.doi.org/10.1097/QCO.0b013e328319bce6
Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993; 328:527–532. http://dx.doi.org/10.1056/NEJM199302253280802
Extensively drug-resistant tuberculosis—United States, 1993-2006.Morbidity and Mortality Weekly Report. 2007; 56:250–253.
World Health Organisation (WHO). WHO report: Global tuberculosis control 2011. Geneva: WHO; 2011.
Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with MDR TB in KwaZulu-Natal, South Africa, 2000–2003. Int J Tuberc Lung Dis. 2010; 14:413.
Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, Moll AP, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis. 2008; 198:1582–1589. http://dx.doi.org/10.1086/592991
Canetti G, Rist N, Grosset J. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation [Article in French]. Rev Tuberc Pneumol (Paris). 1963; 27:217–272.
Agresti A. Building and applying logistic regression models. In Categorical Data Analysis, Second Edition. Hoboken, NJ: John Wiley & Sons; 211–266: 2002. http://dx.doi.org/10.1002/0471249688.ch6
WHO. WHO report: Tuberculosis profile report in Malaysia. Geneva: WHO; 2011 and 2012.
Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007; 45:1290–1295. http://dx.doi.org/10.1086/522537
Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J. 2007; 30:623–626. http://dx.doi.org/10.1183/09031936.00077307
Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986; 133:423–430.
Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis. 1997; 24:S121–S130. http://dx.doi.org/10.1093/clinids/24.Supplement_1.S121
21. Dooley SW, Jarvis WR, Marione WJ, Snider DE, Jr. Multidrug-resistant tuberculosis. Ann Inter Med. 1992; 117(3):257–259. http://dx.doi.org/10.7326/0003-4819-117-3-257
Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. J AM Med Assoc.1993; 270:65–68. http://dx.doi.org/10.1001/jama.1993.03510010071032
Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008; 178(10):1075– 1082. http://dx.doi.org/10.1164/rccm.200801-132OC
Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, et al. Outcome of pulmonary multidrugresistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006; 28:980–985. http://dx.doi.org/10.1183/09031936.06.00125705
Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372:1403–1409. http://dx.doi.org/10.1016/S0140-6736(08)61204-0
Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis. 2008; 12:1182–1189.
Palmero D, Ambroggi M, Brea A, De Lucas M, Fulgenzi A, Martínez D, et al. Treatment an followup of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis. 2004: 8(6):778–784.
Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003; 348:119–128. http://dx.doi.org/10.1056/NEJMoa022928
Escudero E, Pena J, Alvarez-Sala R, Vazquez J, Ortega Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis. 2006; 10:409–414.
Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis. 2005; 9:507–513.
Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005; 365:318–326. http://dx.doi.org/10.1016/S0140-6736(05)70196-3
Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006; 61:158–163. http://dx.doi.org/10.1136/thx.2005.045963
Turett GS, Telzak EE, Torian LV, Blum S, Alland D, Weisfuse I, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis. 1995; 21:1238–1244. http://dx.doi.org/10.1093/clinids/21.5.1238
Elmi OS, Hasan H, Abdullah S, Mat Jeab MZ, Bin Alwi Z, Naing NN. Multidrug resistant tuberculosis and risk factors associated with its development: a retrospective study. J Infect Dev Ctries. 2015; 9(10):1076–1085. http://dx.doi.org/10.3855/jidc.6162
Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010; 182:426–432. http://dx.doi.org/10.1164/rccm.200911-1768OC